Ireland Tariff Rates 2026: 10% on US Imports

Ireland is covered by the EU-US trade deal effective July 1, 2026: most Irish goods now face a 10% net of Column 1 for ordinary goods (15% only in lieu of Section 232 for autos, qualifying semiconductor articles, and drones) US tariff ceiling, replacing the 10% Section 122 tariff that applied from Feb 24 to June 30, 2026. The deal matters enormously for Ireland's pharma-heavy trade profile: EU pharmaceuticals are capped at 15% (shielding Ireland from the threatened 100% branded-pharma tariff), and from Sept 1, 2026 generic pharmaceuticals plus their ingredients and precursors revert to MFN-only rates — typically 0%. Pfizer, Apple, and other US multinationals operating in Ireland drive the trade profile.

Ireland is a major hub for US pharmaceutical and technology companies, with Pfizer, Johnson & Johnson, Eli Lilly, Apple, Google, and Intel operating significant manufacturing and services operations there. The large trade surplus with the US is substantially driven by transfer pricing and intellectual property flows — Ireland's headline trade figures significantly overstate the value of physical goods production. Ireland's 12.5% corporate tax rate (now 15% under OECD Pillar Two for large multinationals) has attracted enormous US foreign direct investment, creating a unique bilateral trade dynamic where many of the largest 'Irish' exporters are actually US companies.

Key Products Imported from Ireland

Top imports include pharmaceuticals and medical devices (the largest category by far, including biologics from Pfizer, Eli Lilly, and Amgen), organic chemicals, optical and medical instruments, computer equipment, and food products (dairy, beef, Irish whiskey). Ireland's pharmaceutical exports alone account for a majority of the bilateral goods trade.

Recent Changes

The timeline: Feb 20, 2026 — SCOTUS struck down IEEPA tariffs 6-3, dropping Ireland from 20% to the 10% Section 122 rate (effective Feb 24). July 1, 2026 — the EU-US trade deal took effect, moving Ireland off Section 122 and onto a 10% net of Column 1 for ordinary goods (15% only in lieu of Section 232 for autos, qualifying semiconductor articles, and drones) ceiling with no stacking. EU pharmaceuticals are capped at 15% under the deal — critical given the July 31, 2026 deadline for pharma onshoring agreements and the threatened 100% tariff on branded pharmaceutical imports from countries outside such deals. From Sept 1, 2026, generic pharmaceuticals plus their ingredients and chemical precursors revert to MFN-only (typically 0%), as do aircraft parts. Alcoholic beverages (Irish whiskey) remain subject to further negotiation. Ireland's pharmaceutical manufacturing continues to expand, with new biologics facilities from Pfizer, Eli Lilly, and Amgen. OECD Pillar Two global minimum tax (15%) is being implemented, which may affect the transfer pricing dynamics that inflate Ireland's trade surplus.

Tips for Importers

Irish pharmaceuticals now pay at most the 15% EU-deal ceiling (up from the interim 10% Section 122 rate, but shielded from the threatened 100% branded-pharma tariff), and from Sept 1, 2026 generics plus their ingredients and precursors go MFN-only — typically 0%, restoring near-duty-free access for that segment. Many 'Irish' exports are products of US companies (Pfizer, Apple, Intel) manufactured in Ireland — verify whether domestic US sourcing alternatives exist to avoid the tariff entirely. Medical devices and organic chemicals pay the flat 15% ceiling. Irish whiskey (HTS 2208.30.30, Free MFN) falls under the 15% ceiling for now, with alcoholic beverages flagged for further negotiation — versus Scotch whisky at the 10% forced-labor tariff that replaced Section 122 on July 24, 2026. The ~$13.50 per proof gallon figure is the federal excise tax on distilled spirits, which applies equally to imported and domestic spirits, so it is not an import tariff. Transfer pricing means the declared customs value of Irish pharmaceutical exports may be scrutinized by CBP.